Cancer Research: Basic research, Clinical trial, Surgery, Chemotherapy, Hormone therapy, Biotechnology, Cancer, Oncology, Epidemiology of cancer, Alternative cancer treatments

Product Description
Cancer research is basic research into cancer in order to identify causes and develop strategies for prevention, diagnosis, treatments and cure. Cancer research ranges from epidemiology, molecular bioscience (bench research) to the performance of clinical trials to evaluate and compare applications of the various cancer treatment. These applications include surgery, radiation therapy, chemotherapy and hormone therapy, and combined treatment modalities such as chemo-radiotherapy. Starting in the mid 1990s, the emphasis in clinical cancer research shifted towards therapies derived from biotechnology research, such as immunotherapy and gene therapy.

Cancer Research: Basic research, Clinical trial, Surgery, Chemotherapy, Hormone therapy, Biotechnology, Cancer, Oncology, Epidemiology of cancer, Alternative cancer treatments

Thrombotech begins stroke treatment clinical trial

Thrombotech begins stroke treatment clinical trial
The Phase I trial is due to be completed by the end of the year.

Read more on Globes Online

Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 SCC Lung Cancer Trial

Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 SCC Lung Cancer Trial
CALGARY , March 30 /March 30, 2010- Oncolytics Biotech Inc. (”Oncolytics”) (TSX:ONC, NASDAQ: ONCY ) announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous …

Read more on dBusinessNews.com

Pevion Biotech’s PEV7 vulvovaginal candidiasis vaccine enters phase-I trial

Pevion Biotech’s PEV7 vulvovaginal candidiasis vaccine enters phase-I trial
Pevion Biotech, the Swiss vaccine company, announced that PEV7, the first vaccine for chronic recurrent thrush – recurrent vulvovaginal candidiasis (VVC) – has entered phase-1 clinical trial.

Read more on PharmaBiz

« Previous Page